Menu
Search
|

Menu

Close
X

Seres Therapeutics Inc MCRB.OQ (NASDAQ Stock Exchange Global Select Market)

6.22 USD
-0.48 (-7.16%)
As of Mar 22
chart
Previous Close 6.70
Open 6.68
Volume 75,721
3m Avg Volume 59,518
Today’s High 6.68
Today’s Low 6.09
52 Week High 9.75
52 Week Low 4.50
Shares Outstanding (mil) 41.05
Market Capitalization (mil) 255.32
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.86 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
28
FY17
32
FY16
19
EPS (USD)
FY18
-2.429
FY17
-2.210
FY16
-3.104
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.10
Price to Sales (TTM)
vs sector
9.03
8.84
Price to Book (MRQ)
vs sector
--
4.60
Price to Cash Flow (TTM)
vs sector
--
40.07
Total Debt to Equity (MRQ)
vs sector
--
17.66
LT Debt to Equity (MRQ)
vs sector
--
13.97
Return on Investment (TTM)
vs sector
-83.73
12.12
Return on Equity (TTM)
vs sector
-1,563.81
13.24

EXECUTIVE LEADERSHIP

Roger Pomerantz
Chairman of the Board, Since 2019
Salary: $581,400.00
Bonus: --
Eric Shaff
President, Chief Executive Officer, Director, Since 2019
Salary: $377,083.00
Bonus: $3,026.00
John Aunins
Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing, Since 2012
Salary: --
Bonus: --
Thomas DesRosier
Chief Legal Officer, Executive Vice President and Secretary, Since 2016
Salary: $243,750.00
Bonus: --
Kevin Horgan
Executive Vice President, Chief Medical Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Sidney St
CAMBRIDGE   MA   02139-4218

Phone: +1617.9459626

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

SPONSORED STORIES